medigraphic.com
ISSN 1996-3521 (Electronic)

2016, Number 22

<< Back Next >>

INFODIR 2016; 12 (22)

Economic evaluation of health technologies in rare diseases and orphan drugs. Assessment on efficiency and equity

Gálvez GAM, Roldán E, Llera VA, Fernández GA, Marrero AM, Peralta RJA

Language: Spanish
References: 16
Page: 3-8
PDF size: 231.90 Kb.


ABSTRACT

Background: Evaluation of health technologies in rare diseases and orphan drugs has become focus of attention for scientists, managers and society in general. This polemic issue needs evaluations and analysis from different perspectives. Economic evaluation of technologies can contribute to improve decision-making and resources allocation.
Objective: Description and discussion on a set of issues being considered relevant to tackle economic evaluation of health technologies in rare diseases and orphan drugs.
Method: A bibliographical, documentary review was carried out on this subject, as well as consultation to researchers and managers on subject-related weaknesses.
Results: Efficiency, equity and sustainability of funding technology in rare diseases and orphan drugs were the most discussed aspects. A set of weaknesses to take into account as to deepen in the economic analysis of the subject was identified.


REFERENCES

  1. Darbá Josep. Consideraciones económicas para la evaluación de los medicamentos huérfanos en las decisiones de financiación en España. Pharmacoeconomics Spanish Research Articles. 2013. DOI 10.1007/s40277- 013-0014-7.

  2. Kontoghiorghe NC, Andreou N, Constantinou K, Kontoghiorghes GJ. World Health dilemmas: orphan and rare diseases, orphan drugs and orphan patients. World J Methodol. 2014; 4(3): 163-88.

  3. European Commission. European Commission Regulation (EC) No. 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Off J Eur Communities [Internet]. 2000 [cited 23 Nov 2015]; L 18: [about 5p.]. Available from: http://ec.europa.eu/health/files/eudralex/vol- 1/reg_2000_141/reg_2000_141_en.pdf

  4. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? Q J Med.2005;98:829–36.

  5. Hyry HI, Manuel J, Cox TM, Roos JC. Compassionate use of orphan drugs. Orphanet J Rare Dis [Internet]. 2015 [cited 7 Dec 2015]; 10(100): [about 9p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26292942

  6. Winstone J, Chadda S, Ralston S, Sajosi P. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments. Orphanet J Rare Dis [Internet]. 2015 [cited 10 Dec 2015]; 10(139): [about 8p.]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625856/

  7. Pastor Ma de las M. Modelo de gestión farmacéutica los medicamentos huérfanos. Consideraciones sobre el coste efectividad. Anexo IV. En: Rodríguez-Santana IP. El Modelo de Futuro de Gestión de la Salud. Propuestas para un debate [Internet]. Madrid: Bamberg; 2011 [citado 12 Jul 2011]. p. 38- 43. Disponible en: http://static.correofarmaceutico.com/docs/2011/04/ modelo_futuro_gestion.pdf

  8. National Institute for Health and Clinical Excellence. Appraising orphan drugs [Internet]. [cited Jun 12 2011]. Available from: http://www.nice.org.uk/niceMedia/pdf/smt/120705item4.pdf

  9. Orofino J, Soto J, Casado MA, Oyagüez I. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy. 2010;8(5):301–15.

  10. Wang B, Kesselheim AS. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States 2005-14: systematic review. BMJ [Internet]. 2015 [cited 1 Dec 2015]; 351(h4679): [about 8p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26400844

  11. Gammie T, Lu CY, Babar ZU. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS One [Internet]. 2015 [cited 1 Dec 2015]; 10(10): [about 9p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26451948

  12. Rhee TG. Policymaking for Orphan Drugs and Its Challenges. AMA J Ethics. 2015; 17(8):776-9.

  13. Schuller Y, Hollak CE, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review. Orphanet J Rare Dis [Internet]. 2015 [cited 1 Dec 2015]; 10(92): [about 9p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26223689

  14. Onakpoya IJ, Spencer EA, Thompson MJ, Heneghan CJ. Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open [Internet]. 2015 Jun 24 [cited 2 Dec 2015]; 5(6):e007199. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26109112

  15. Orpha.net [Internet]. Paris: INSERM; c1997 [updated Nov 15 2011; cited Jun 8 2014]. Available from: http://www.orpha.net/consor/cgibin/ index.php?lng=ES.

  16. Gálvez A, Marrero M, Peralta J. Encuentro de Enfermedades Raras Cuba Ecuador. Universidad de Ciencias Médicas de la Habana. 2014.




2020     |     www.medigraphic.com